Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenon and Genentech, a member of the Roche Group, have entered an agreement to discover and develop compounds and companion diagnostics for the potential pain treatment.
Subscribe to our email newsletter
As per the alliance, Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products.
Xenon on the other hand is entitled to receive an undisclosed upfront payment, research funding and research, development and commercialization milestone payments, totaling up to $646m.
Xenon will also receive royalties on sales of products resulting from the collaboration.
Xenon president and CEO Simon Pimstone said Genentech would be a suitable partner as the two companies share a common emphasis on using human genetics for drug development.
"Further, this collaboration allows Xenon to both deepen and broaden our pipeline of novel medicines in development," Pimstone added.